The Eye is the Window to Systemic Health.

The Operator

Dr. Tao Ke is a seasoned AI strategist and transformation architect who bridges deep tech, global strategy, and capital formation. He holds a Ph.D. in computational chemistry from MIT, where he was among the earliest researchers applying machine learning principles to molecular modeling—well before AI entered the mainstream. Since then, he has spent over two decades leading large-scale strategy, technology, and growth programs at McKinsey, Bain, and Accenture, advising Fortune 500s and scaling ventures from idea to institutional capital readiness. Tao served as Global Vice President and Head of Strategy for Greater China at Disney, where he led enterprise-wide initiatives around regional expansion, digital partnerships, and innovation acceleration. This corporate leadership experience equipped him with a rare ability to connect boardroom priorities with ground-level execution—across both Western and Asian business environments. In recent years, Tao has transitioned into hands-on company building. He co-led an AI SaaS platform from inception to over $30 million in annual recurring revenue (ARR) and a successful NASDAQ listing in late 2024, within just four years. As a fractional CFO and strategic co-founder, he installed investor-grade financial systems, drove GTM design, and aligned operations with long-term M&A and IPO paths—all while preserving capital efficiency and founder ownership. Currently based in Southern California, Tao focuses on medtech and biotechnology, where AI-enabled platforms are transforming diagnostics, remote care, and longitudinal health monitoring. He now works closely with high-potential startups as a fractional CFO and strategic advisor, including serving as a core strategy advisor to AnX, a nextgeneration medical robotics company. In this capacity, he not only helps shape productmarket fit and financial roadmaps but also serves as a bridge between North American healthtech ecosystems and strategic capital across Asia. Dr. Tao Ke is particularly well-positioned to help early-stage founders, cross-border ventures, and growth-stage medtech innovators who need more than just advice—they need a partner who can build with them, raise with them, and exit with them.